title: Isolation of novel Afipia septicemium and identification of previously unknown bacteria Bradyrhizobium sp. OHSU_III from blood of patients with poorly defined illnesses.
abstract: Cultures previously set up for isolation of mycoplasmal agents from blood of patients with poorly-defined illnesses, although not yielding positive results, were cryopreserved because of suspicion of having low numbers of unknown microbes living in an inactive state in the broth. We re-initiated a set of 3 cultures for analysis of the "uncultivable" or poorly-grown microbes using NGS technology. Broth of cultures from 3 blood samples, submitted from OHSU between 2000 and 2004, were inoculated into culture flasks containing fresh modified SP4 medium and kept at room temperature (RT), 30°C and 35°C. The cultures showing evidence of microbial growth were expanded and subjected to DNA analysis by genomic sequencing using Illumina MiSeq. Two of the 3 re-initiated blood cultures kept at RT after 7-8 weeks showed evidence of microbial growth that gradually reached into a cell density with detectable turbidity. The microbes in the broth when streaked on SP4 agar plates produced microscopic colonies in ∼ 2 weeks. Genomic studies revealed that the microbes isolated from the 2 blood cultures were a novel Afipia species, tentatively named Afipia septicemium. Microbes in the 3(rd) culture (OHSU_III) kept at RT had a limited level of growth and could not reach a plateau with high cell density. Genomic sequencing identified the microbe in the culture as a previously unknown species of Bradyrhizobium bacteria. This study reports on the isolation of novel Afipia and Bradyrhizobium species. Isolation of Bradyrhizobium species bacteria has never been reported in humans. The study also reveals a previously unrecognized nature of hematogenous infections by the 2 unique groups of Bradyrhizobiaceae. Our studies show that improvement of culture system plus effective use of NGS technology can facilitate findings of infections by unusual microbes in patients having poorly-defined, sometimes mysterious illnesses.
authors.affiliation: Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America.
authors.forename: Shyh-Ching
authors.initials: SC
authors.lastname: Lo
authors.forename: Guo-Chiuan
authors.initials: GC
authors.lastname: Hung
authors.forename: Bingjie
authors.initials: B
authors.lastname: Li
authors.forename: Haiyan
authors.initials: H
authors.lastname: Lei
authors.forename: Tianwei
authors.initials: T
authors.lastname: Li
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Nagamine
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Shien
authors.initials: S
authors.lastname: Tsai
authors.forename: Richard
authors.initials: R
authors.lastname: Bryant
mesh_terms: D000328:Adult; D020622:Afipia / Q000166:cytology / Q000254:growth & development / Q000302:isolation & purification* / Q000648:ultrastructure; D001482:Base Composition / Q000235:genetics; D001483:Base Sequence; D020369:Bradyrhizobium / Q000166:cytology / Q000254:growth & development / Q000302:isolation & purification* / Q000648:ultrastructure; D015925:Cryopreservation; D005260:Female; D005798:Genes, Bacterial / Q000235:genetics; D016905:Gram-Negative Bacterial Infections / Q000097:blood* / Q000382:microbiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009876:Operon / Q000235:genetics; D010802:Phylogeny; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D016415:Sequence Alignment; D017422:Sequence Analysis, DNA
chemical_list: D012336:RNA, Ribosomal, 16S